Supplementary appendix 6. Main analysis, sensitivity analysis, and direct comparison for serious vascular events.

Main analysis, sensitivity analysis, and direct comparison for serious vascular events

Comparisons	Network meta-analysis								Direct comparisons
	All trials (n=36)	Low risk of bias (n=29)	Allocation concealed (n=33)	Adjudication blinded (n=31)	Attrition bias (n=31)	Trials with≥24 months of follow-up (n=19)	Trials initiated after 1980 (n=28)	A2=Aspirin 75-330 mgdaily (n=36)	
P vs D	0.88 (0.75-1.06)	0.89 (0.75-1.09)	0.75 (0.75-1.06)	0.89 (0.75-1.08)	0.88 (0.75-1.06)	0.86 (0.71-1.05)	0.88 (0.74-1.08)	0.88 (0.75-1.05)	0.87 (0.73-1.03)
P vs A1	0.86 (0.74-1.00)	0.87 (0.74-1.02)	0.86 (0.74-1.00)	0.87 (0.74-1.01)	0.86 (0.74-1.00)	0.85 (0.72-1.01)	0.86 (0.73-1.01)	0.86 (0.74-0.99)	0.86 (0.72-1.02)
P vs A2	0.83 (0.71-0.96)	0.80 (0.68-0.95)	0.83 (0.71-0.96)	0.80 (0.68-0.94)	0.83 (0.71-0.97)	0.84 (0.71-1.00)	0.83 (0.70-0.97)	0.83 (0.75-0.93)	0.81 (0.63-1.03)
P vs A3	0.84 (0.73-0.97)	0.85 (0.74-0.98)	0.84 (0.73-0.97)	0.85 (0.74-0.98)	0.85 (0.73-0.97)	0.87 (0.74-1.02)	0.84 (0.72-0.97)	—	0.85 (0.67-1.07)
P vs A4	0.82 (0.72-0.93)	0.84 (0.73-0.96)	0.82 (0.72-0.93)	0.82 (0.72-0.93)	0.83 (0.73-0.95)	0.86 (0.75-0.99)	0.81 (0.67-0.97)	0.82 (0.73-0.92)	0.83 (0.71-0.98)
P vs AD1	0.72 (0.63-0.83)	0.74 (0.64-0.87)	0.72 (0.63-0.83)	0.74 (0.64-0.86)	0.72 (0.63-0.83)	0.67 (0.56-0.79)	0.72 (0.62-0.84)	0.72 (0.63-0.83)	0.66 (0.55-0.79)
P vs AD2	0.70 (0.59-0.83)	0.74 (0.56-0.97)	0.69 (0.58-0.82)	0.70 (0.59-0.82)	0.70 (0.58-0.82)	0.76 (0.59-1.02)	0.68 (0.53-0.85)	0.70 (0.60-0.83)	0.65 (0.54-0.78)
P vs TC	0.80 (0.68-0.93)	0.83 (0.70-0.98)	0.81 (0.69-0.95)	0.81 (0.69-0.95)	0.82 (0.70-0.96)	0.81 (0.67-0.97)	0.80 (0.66-0.97)	0.80 (0.68-0.93)	0.77 (0.58-1.03)
P vs A+TC	0.94 (0.32-2.17)	—	0.99 (0.34-2.69)	—	—	—	0.92 (0.33-1.97)	0.91 (0.30-2.06)	—
P vs C	0.74 (0.65-0.86)	0.75 (0.65-0.88)	0.74 (0.65-0.86)	0.75 (0.65-0.88)	0.74 (0.65-0.87)	0.67 (0.53-0.84)	0.74 (0.64-0.88)	0.74 (0.65-0.86)	—
P vs A+C	0.70 (0.59-0.83)	0.69 (0.59-0.83)	0.70 (0.59-0.83)	0.69 (0.59-0.83)	0.70 (0.59-0.83)	0.72 (0.58-0.91)	0.69 (0.58-0.83)	0.70 (0.60-0.83)	—
P vs TF	0.82 (0.63-1.04)	0.89 (0.67-1.17)	0.89 (0.67-1.16)	0.89 (0.67-1.15)	0.89 (0.67-1.16)	0.83 (0.60-1.09)	0.81 (0.62-1.05)	0.81 (0.64-1.02)	—
P vs CL	0.57 (0.45-0.72)	0.55 (0.43-0.71)	0.57 (0.45-0.72)	0.56 (0.44-0.71)	0.56 (0.45-0.72)	0.59 (0.46-0.78)	0.56 (0.44-0.72)	0.57 (0.46-0.72)	0.52 (0.34-0.79)
P vs A+CL	0.94 (0.47-2.22)	0.96 (0.51-2.38)	0.96 (0.47-2.33)	1.00 (0.50-2.56)	0.95 (0.46-2.50)	—	0.92 (0.46-2.27)	0.94 (0.47-2.22)	—
D vs A1	0.97 (0.80-1.16)	0.97 (0.80-1.16)	0.97 (0.80-1.16)	0.97 (0.80-1.17)	0.97 (0.80-1.17)	0.99 (0.81-1.20)	0.97 (0.79-1.17)	0.97 (0.81-1.15)	0.99 (0.83-1.18)
D vs A2	0.93 (0.76-1.15)	0.88 (0.70-1.12)	0.93 (0.76-1.15)	0.88 (0.71-1.11)	0.93 (0.76-1.15)	0.97 (0.78-1.23)	0.93 (0.74-1.16)	0.93 (0.79-1.12)	—
D vs A3	0.95 (0.78-1.15)	0.95 (0.77-1.16)	0.95 (0.78-1.15)	0.95 (0.78-1.15)	0.95 (0.78-1.16)	1.01 (0.80-1.26)	0.95 (0.76-1.17)	—	—
D vs A4	0.93 (0.75-1.15)	0.94 (0.74-1.16)	0.93 (0.75-1.13)	0.92 (0.74-1.13)	0.94 (0.75-1.16)	1.00 (0.79-1.26)	0.91 (0.70-1.17)	0.92 (0.75-1.12)	—
D vs AD1	0.81 (0.68-0.97)	0.82 (0.68-1.00)	0.81 (0.68-0.97)	0.82 (0.68-0.99)	0.81 (0.68-0.98)	0.76 (0.63-0.94)	0.81 (0.67-0.98)	0.81 (0.68-0.97)	0.76 (0.63-0.91)
D vs AD2	0.80 (0.62-1.01)	0.83 (0.58-1.13)	0.78 (0.61-0.99)	0.78 (0.60-0.98)	0.79 (0.61-1.00)	0.90 (0.64-1.24)	0.76 (0.56-1.02)	0.79 (0.62-1.00)	—

Supplementary appendix 6. Main analysis, sensitivity analysis, and direct comparison for serious vascular events.

D vs TC	0.90 (0.71-1.13)	0.92 (0.72-1.17)	0.92 (0.72-1.15)	0.91 (0.72-1.14)	0.93 (0.73-1.16)	0.94 (0.71-1.21)	0.91 (0.70-1.17)	0.90 (0.71-1.11)	—
D vs A+TC	1.06 (0.35-2.44)	—	1.11 (0.38-3.03)	—	—	—	1.04 (0.37-2.24)	1.03 (0.34-2.34)	—
D vs C	0.84 (0.69-1.02)	0.85 (0.69-1.04)	0.84 (0.69-1.02)	0.84 (0.69-1.02)	0.84 (0.69-1.03)	0.78 (0.60-1.00)	0.84 (0.67-1.04)	0.84 (0.69-1.01)	—
D vs A+C	0.79 (0.63-0.98)	0.78 (0.62-0.97)	0.79 (0.63-0.97)	0.78 (0.62-0.96)	0.79 (0.63-0.98)	0.85 (0.64-1.10)	0.79 (0.62-0.99)	0.79 (0.64-0.97)	—
D vs TF	0.93 (0.69-1.22)	1.00 (0.72-1.34)	1.00 (0.73-1.35)	0.99 (0.72-1.35)	1.00 (0.73-1.34)	0.95 (0.67-1.30)	0.92 (0.66-1.23)	0.92 (0.69-1.19)	—
D vs CL	0.65 (0.48-0.86)	0.63 (0.46-0.84)	0.65 (0.49-0.85)	0.63 (0.46-0.82)	0.65 (0.48-0.85)	0.70 (0.50-0.94)	0.65 (0.48-0.85)	0.65 (0.50-0.85)	—
D vs A+CL	1.26 (0.52-2.50)	1.25 (0.54-2.66)	1.29 (0.53-2.61)	1.32 (0.55-2.84)	1.29 (0.52-2.80)	—	1.23 (0.51-2.61)	1.25 (0.52-2.57)	—
A1 vs A2	0.96 (0.81-1.16)	0.92 (0.75-1.14)	0.96 (0.81-1.16)	0.92 (0.76-1.12)	0.96 (0.81-1.16)	0.99 (0.81-1.23)	0.96 (0.79-1.18)	0.97 (0.85-1.12)	—
A1 vs A3	0.98 (0.85-1.14)	0.98 (0.84-1.15)	0.98 (0.85-1.14)	0.98 (0.84-1.14)	0.99 (0.84-1.15)	1.03 (0.86-1.22)	0.98 (0.83-1.15)	—	1.05 (0.86-1.27)
A1 vs A4	0.96 (0.79-1.16)	0.97 (0.79-1.17)	0.96 (0.79-1.15)	0.95 (0.79-1.15)	0.97 (0.80-1.17)	1.02 (0.82-1.25)	0.95 (0.75-1.18)	0.96 (0.80-1.14)	—
A1 vs AD1	0.84 (0.72-0.98)	0.85 (0.72-1.01)	0.84 (0.72-0.99)	0.85 (0.73-1.00)	0.84 (0.72-0.99)	0.78 (0.65-0.95)	0.84 (0.71-1.00)	0.84 (0.72-0.98)	0.77 (0.64-0.93)
A1 vs AD2	0.82 (0.66-1.02)	0.86 (0.62-1.16)	0.81 (0.64-1.01)	0.80 (0.64-1.00)	0.81 (0.64-1.02)	0.89 (0.66-1.25)	0.79 (0.59-1.04)	0.82 (0.66-1.02)	—
A1 vs TC	0.93 (0.76-1.15)	0.94 (0.76-1.18)	0.93 (0.76-1.16)	0.93 (0.75-1.16)	0.95 (0.78-1.18)	0.93 (0.74-1.20)	0.93 (0.75-1.19)	0.92 (0.76-1.14)	—
A1 vs A+TC	0.86 (0.37-2.56)	—	0.90 (0.40-3.03)	—	—	—	0.87 (0.38-2.33)	0.83 (0.35-2.44)	—
A1 vs C	0.86 (0.74-1.03)	0.87 (0.74-1.04)	0.86 (0.74-1.03)	0.86 (0.74-1.03)	0.86 (0.74-1.03)	0.78 (0.61-1.01)	0.86 (0.72-1.04)	0.86 (0.74-1.02)	—
A1 vs A+C	0.81 (0.68-0.98)	0.80 (0.66-0.98)	0.81 (0.68-0.98)	0.80 (0.67-0.97)	0.81 (0.68-0.99)	0.85 (0.67-1.09)	0.81 (0.67-1.00)	0.81 (0.68-0.98)	—
A1 vs TF	0.94 (0.73-1.23)	1.01 (0.77-1.35)	1.01 (0.78-1.37)	1.00 (0.77-1.33)	1.01 (0.78-1.35)	0.94 (0.70-1.28)	0.93 (0.71-1.23)	0.93 (0.73-1.20)	—
A1 vs CL	0.66 (0.51-0.87)	0.64 (0.48-0.85)	0.66 (0.51-0.87)	0.64 (0.49-0.84)	0.66 (0.50-0.87)	0.69 (0.52-0.95)	0.66 (0.51-0.87)	0.67 (0.52-0.86)	—
A1 vs A+CL	1.10 (0.54-2.56)	1.11 (0.57-2.70)	1.12 (0.54-2.70)	1.15 (0.57-2.94)	1.11 (0.54-2.94)	—	1.08 (0.54-2.70)	1.10 (0.55-2.63)	—
A2 vs A3	1.02 (0.87-1.19)	1.06 (0.88-1.28)	1.01 (0.86-1.19)	1.06 (0.89-1.27)	1.02 (0.86-1.20)	1.03 (0.84-1.26)	1.01 (0.85-1.20)	—	—
A2 vs A4	0.99 (0.82-1.18)	1.05 (0.85-1.28)	0.99 (0.82-1.19)	1.03 (0.84-1.26)	1.01 (0.82-1.22)	1.02 (0.82-1.27)	0.98 (0.78-1.21)	0.98 (0.84-1.14)	—
A2 vs AD1	0.87 (0.76-1.00)	0.93 (0.78-1.12)	0.87 (0.75-1.00)	0.93 (0.78-1.11)	0.87 (0.75-1.01)	0.79 (0.65-0.95)	0.87 (0.75-1.01)	0.87 (0.77-0.96)	0.93 (0.59-1.45)*
A2 vs AD2	0.85 (0.67-1.05)	0.93 (0.66-1.27)	0.83 (0.66-1.04)	0.87 (0.69-1.09)	0.84 (0.66-1.06)	0.92 (0.66-1.26)	0.82 (0.61-1.07)	0.84 (0.69-1.02)	—
A2 vs TC	0.97 (0.78-1.18)	1.04 (0.82-1.30)	0.98 (0.79-1.20)	1.02 (0.81-1.27)	0.99 (0.80-1.22)	0.96 (0.74-1.22)	0.97 (0.77-1.22)	0.95 (0.79-1.13)	—
A2 vs A+TC	1.13 (0.38-2.62)	—	1.19 (0.41-3.23)	—	—	—	1.11 (0.40-2.42)	1.09 (0.36-2.45)	—

Supplementary appendix 6. Main analysis, sensitivity analysis, and direct comparison for serious vascular events.

A2 vs C	0.90 (0.77-1.05)	0.95 (0.79-1.13)	0.90 (0.77-1.05)	0.94 (0.79-1.12)	0.90 (0.77-1.05)	0.80 (0.62-1.01)	0.90 (0.76-1.06)	0.89 (0.80-0.99)	—
A2 vs A+C	0.84 (0.72-0.98)	0.88 (0.74-1.03)	0.84 (0.72-0.98)	0.87 (0.74-1.03)	0.85 (0.72-0.98)	0.87 (0.71-1.05)	0.84 (0.72-0.99)	0.84 (0.74-0.95)	0.82 (0.67-1.00)
A2 vs TF	0.99 (0.74-1.28)	1.12 (0.82-1.50)	1.07 (0.80-1.41)	1.11 (0.82-1.47)	1.07 (0.80-1.42)	0.98 (0.70-1.32)	0.98 (0.73-1.27)	0.97 (0.78-1.18)	—
A2 vs CL	0.69 (0.55-0.86)	0.70 (0.55-0.87)	0.69 (0.55-0.85)	0.70 (0.56-0.86)	0.69 (0.55-0.85)	0.71 (0.55-0.90)	0.69 (0.55-0.86)	0.69 (0.56-0.85)	0.70 (0.55-0.90)
A2 vs A+CL	1.34 (0.55-2.65)	1.40 (0.63-2.96)	1.37 (0.57-2.76)	1.47 (0.64-3.09)	1.38 (0.56-2.95)	—	1.31 (0.56-2.77)	1.32 (0.57-2.70)	1.03 (0.06-16.7)
A3 vs A4	0.98 (0.83-1.15)	0.99 (0.83-1.17)	0.98 (0.82-1.15)	0.97 (0.82-1.15)	0.99 (0.82-1.17)	0.99 (0.82-1.20)	0.97 (0.79-1.17)	—	0.97 (0.77-1.23)
A3 vs AD1	0.85 (0.75-0.98)	0.87 (0.75-1.02)	0.85 (0.75-0.98)	0.87 (0.76-1.01)	0.85 (0.74-0.99)	0.76 (0.62-0.94)	0.85 (0.74-1.00)	—	—
A3 vs AD2	0.84 (0.68-1.03)	0.87 (0.63-1.17)	0.83 (0.66-1.01)	0.82 (0.66-1.01)	0.83 (0.66-1.02)	0.88 (0.65-1.20)	0.81 (0.61-1.05)	—	—
A3 vs TC	0.94 (0.78-1.15)	0.96 (0.80-1.18)	0.96 (0.79-1.16)	0.95 (0.79-1.16)	0.96 (0.80-1.18)	0.92 (0.74-1.16)	0.95 (0.78-1.18)	—	—
A3 vs A+TC	0.88 (0.37-2.56)	—	0.92 (0.41-3.13)	—	—	—	0.89 (0.40-2.38)	—	—
A3 vs C	0.88 (0.78-1.01)	0.89 (0.79-1.01)	0.88 (0.78-1.00)	0.88 (0.79-1.01)	0.88 (0.78-1.01)	0.76 (0.59-0.99)	0.88 (0.78-1.02)	—	0.90 (0.79-1.04)
A3 vs A+C	0.83 (0.71-0.96)	0.82 (0.70-0.95)	0.83 (0.71-0.96)	0.82 (0.71-0.96)	0.83 (0.71-0.96)	0.83 (0.68-1.03)	0.83 (0.71-0.97)	—	0.86 (0.68-1.08)
A3 vs TF	0.96 (0.78-1.20)	1.03 (0.82-1.32)	1.04 (0.83-1.32)	1.03 (0.82-1.32)	1.03 (0.83-1.32)	0.93 (0.73-1.19)	0.95 (0.77-1.19)	—	0.94 (0.69-1.28)
A3 vs CL	0.67 (0.53-0.87)	0.65 (0.50-0.86)	0.68 (0.53-0.87)	0.65 (0.51-0.85)	0.67 (0.52-0.87)	0.68 (0.51-0.92)	0.68 (0.52-0.88)	—	0.65 (0.23-1.85)
A3 vs A+CL	1.12 (0.56-2.56)	1.14 (0.59-2.78)	1.15 (0.56-2.70)	1.18 (0.60-3.03)	1.14 (0.55-2.94)	—	1.10 (0.56-2.70)	—	—
A4 vs AD1	0.88 (0.74-1.05)	0.88 (0.74-1.08)	0.88 (0.74-1.05)	0.89 (0.75-1.09)	0.87 (0.72-1.04)	0.77 (0.62-0.96)	0.88 (0.72-1.11)	0.88 (0.74-1.05)	—
A4 vs AD2	0.86 (0.72-1.03)	0.88 (0.67-1.13)	0.84 (0.70-1.01)	0.85 (0.70-1.02)	0.84 (0.69-1.01)	0.88 (0.70-1.15)	0.84 (0.62-1.12)	0.86 (0.71-1.02)	0.94 (0.71-1.23)
A4 vs TC	0.97 (0.85-1.11)	0.98 (0.85-1.12)	0.99 (0.87-1.12)	0.99 (0.87-1.12)	0.98 (0.86-1.12)	0.93 (0.79-1.10)	0.99 (0.86-1.15)	0.97 (0.85-1.10)	0.97 (0.71-1.32)*
A4 vs A+TC	0.90 (0.38-2.63)	—	0.94 (0.42-3.23)	—	—	—	0.93 (0.41-2.44)	0.88 (0.37-2.50)	—
A4 vs C	0.90 (0.76-1.09)	0.90 (0.75-1.09)	0.90 (0.76-1.09)	0.91 (0.77-1.1)	0.89 (0.75-1.09)	0.77 (0.59-1.01)	0.92 (0.75-1.15)	0.90 (0.76-1.09)	—
A4 vs A+C	0.85 (0.70-1.04)	0.83 (0.68-1.02)	0.85 (0.70-1.04)	0.85 (0.7-1.04)	0.84 (0.69-1.04)	0.84 (0.66-1.09)	0.86 (0.69-1.09)	0.85 (0.71-1.04)	—
A4 vs TF	0.98 (0.76-1.28)	1.04 (0.79-1.41)	1.06 (0.81-1.43)	1.05 (0.79-1.43)	1.04 (0.79-1.43)	0.93 (0.69-1.30)	0.99 (0.75-1.33)	0.98 (0.76-1.28)	—
A4 vs CL	0.69 (0.53-0.91)	0.66 (0.51-0.88)	0.69 (0.53-0.91)	0.68 (0.52-0.88)	0.68 (0.52-0.90)	0.68 (0.51-0.93)	0.70 (0.53-0.94)	0.70 (0.55-0.91)	—
A4 vs A+CL	1.15 (0.56-2.70)	1.15 (0.59-2.86)	1.18 (0.57-2.86)	1.20 (0.61-3.13)	1.15 (0.55-3.03)	—	1.14 (0.57-2.86)	1.15 (0.57-2.78)	—
AD1 vs AD2	0.98 (0.79-1.20)	1.00 (0.72-1.34)	0.96 (0.77-1.18)	0.94 (0.75-1.16)	0.97 (0.77-1.20)	1.17 (0.84-1.60)	0.94 (0.71-1.22)	0.97 (0.79-1.19)	—

Supplementary appendix 6. Main analysis, sensitivity analysis, and direct comparison for serious vascular events.

AD1 vs TC	1.11 (0.91-1.34)	1.12 (0.90-1.36)	1.13 (0.92-1.37)	1.10 (0.89-1.34)	1.14 (0.93-1.39)	1.21 (0.94-1.55)	1.12 (0.89-1.39)	1.10 (0.90-1.33)	—
AD1 vs A+TC	1.30 (0.43-2.98)	—	1.37 (0.47-3.70)	—	—	—	1.28 (0.46-2.75)	1.26 (0.42-2.84)	—
AD1 vs C	1.03 (0.93-1.16)	1.02 (0.90-1.15)	1.03 (0.93-1.16)	1.02 (0.91-1.14)	1.03 (0.92-1.16)	1.01 (0.86-1.17)	1.03 (0.91-1.18)	1.03 (0.93-1.15)	1.00 (0.93-1.09)
AD1 vs A+C	0.97 (0.83-1.13)	0.94 (0.79-1.10)	0.97 (0.83-1.13)	0.95 (0.80-1.11)	0.97 (0.83-1.13)	1.10 (0.85-1.39)	0.97 (0.82-1.14)	0.97 (0.84-1.12)	—
AD1 vs TF	1.14 (0.87-1.45)	1.20 (0.90-1.57)	1.23 (0.93-1.61)	1.20 (0.90-1.56)	1.23 (0.92-1.60)	1.24 (0.88-1.68)	1.13 (0.85-1.46)	1.13 (0.89-1.41)	—
AD1 vs CL	0.80 (0.62-1.01)	0.76 (0.57-0.97)	0.80 (0.62-1.00)	0.76 (0.58-0.97)	0.80 (0.61-1.01)	0.90 (0.67-1.20)	0.80 (0.61-1.01)	0.80 (0.63-1.00)	—
AD1 vs A+CL	1.54 (0.65-3.04)	1.50 (0.67-3.19)	1.58 (0.66-3.18)	1.60 (0.68-3.48)	1.58 (0.64-3.41)	—	1.51 (0.64-3.16)	1.53 (0.66-3.11)	—
AD2 vs TC	1.14 (0.92-1.41)	1.11 (0.84-1.52)	1.16 (0.94-1.47)	1.16 (0.94-1.45)	1.18 (0.95-1.47)	1.06 (0.78-1.41)	1.18 (0.89-1.61)	1.12 (0.93-1.39)	—
AD2 vs A+TC	1.05 (0.45-3.13)	—	1.12 (0.49-3.85)	—	—	—	1.10 (0.47-3.13)	1.02 (0.43-2.94)	—
AD2 vs C	1.05 (0.85-1.32)	1.02 (0.76-1.41)	1.08 (0.87-1.35)	1.08 (0.88-1.35)	1.06 (0.86-1.35)	0.85 (0.61-1.23)	1.10 (0.84-1.47)	1.05 (0.86-1.32)	—
AD2 vs A+C	0.99 (0.79-1.27)	0.94 (0.69-1.32)	1.01 (0.80-1.28)	1.00 (0.80-1.27)	1.00 (0.79-1.28)	0.93 (0.67-1.33)	1.03 (0.78-1.39)	0.99 (0.80-1.27)	—
AD2 vs TF	1.15 (0.85-1.56)	1.19 (0.82-1.75)	1.25 (0.93-1.75)	1.25 (0.93-1.72)	1.25 (0.92-1.75)	1.08 (0.71-1.56)	1.18 (0.85-1.69)	1.14 (0.86-1.54)	—
AD2 vs CL	0.81 (0.61-1.09)	0.75 (0.52-1.11)	0.82 (0.62-1.10)	0.80 (0.60-1.08)	0.81 (0.61-1.10)	0.76 (0.53-1.12)	0.84 (0.61-1.19)	0.81 (0.63-1.1)	—
AD2 vs A+CL	1.35 (0.66-3.23)	1.30 (0.64-3.33)	1.39 (0.68-3.33)	1.43 (0.71-3.7)	1.37 (0.65-3.57)	—	1.35 (0.66-3.57)	1.35 (0.65-3.23)	—
TC vs A+TC	1.17 (0.40-2.66)	—	1.22 (0.43-3.18)	—	—	—	1.15 (0.42-2.43)	1.14 (0.39-2.54)	1.05 (0.42-2.61)
TC vs C	0.93 (0.77-1.14)	0.91 (0.75-1.12)	0.91 (0.75-1.12)	0.93 (0.76-1.14)	0.91 (0.74-1.11)	0.83 (0.62-1.11)	0.92 (0.75-1.16)	0.93 (0.78-1.14)	1.10 (0.64-1.89)
TC vs A+C	0.87 (0.70-1.09)	0.84 (0.68-1.05)	0.85 (0.69-1.08)	0.85 (0.69-1.06)	0.85 (0.68-1.06)	0.90 (0.69-1.19)	0.86 (0.69-1.10)	0.88 (0.71-1.09)	—
TC vs TF	1.03 (0.76-1.34)	1.09 (0.79-1.46)	1.10 (0.80-1.47)	1.10 (0.79-1.47)	1.09 (0.79-1.46)	1.03 (0.72-1.41)	1.02 (0.74-1.36)	1.03 (0.77-1.35)	—
TC vs CL	0.71 (0.54-0.94)	0.67 (0.51-0.91)	0.70 (0.53-0.94)	0.68 (0.52-0.91)	0.69 (0.52-0.92)	0.74 (0.54-1.02)	0.70 (0.52-0.95)	0.72 (0.56-0.95)	—
TC vs A+CL	1.18 (0.58-2.78)	1.16 (0.59-2.94)	1.19 (0.56-2.86)	1.22 (0.60-3.23)	1.16 (0.56-3.03)	—	1.15 (0.57-2.86)	1.19 (0.58-2.86)	—
A+TC vs C	0.79 (0.35-2.38)	—	0.75 (0.28-2.22)	—	—	—	0.81 (0.37-2.27)	0.81 (0.36-2.50)	—
A+TC vs A+C	0.75 (0.32-2.22)	—	0.70 (0.26-2.08)	—	—	—	0.76 (0.34-2.13)	0.77 (0.34-2.33)	—
A+TC vs TF	1.11 (0.38-2.68)	—	1.14 (0.33-2.68)	—	—	—	1.09 (0.39-2.55)	1.13 (0.39-2.73)	—
A+TC vs CL	0.61 (0.27-1.85)	—	0.58 (0.23-1.72)	—	—	—	0.61 (0.27-1.75)	0.63 (0.27-1.89)	—
A+TC vs A+CL	1.01 (0.58-4.17)	—	0.99 (0.36-4.17)	—	—	—	1.01 (0.38-3.85)	1.04 (0.38-4.55)	—

Supplementary appendix 6. Main analysis, sensitivity analysis, and direct comparison for serious vascular events.

C vs A+C	0.94 (0.82-1.07)	0.93 (0.80-1.06)	0.94 (0.82-1.07)	0.93 (0.81-1.06)	0.94 (0.82-1.07)	1.10 (0.82-1.45)	0.94 (0.81-1.08)	0.95 (0.83-1.07)	0.93 (0.81-1.07)
C vs TF	1.10 (0.85-1.40)	1.18 (0.89-1.53)	1.19 (0.91-1.55)	1.18 (0.89-1.52)	1.19 (0.90-1.54)	1.24 (0.85-1.73)	1.10 (0.83-1.40)	1.10 (0.86-1.37)	—
C vs CL	0.77 (0.60-0.98)	0.74 (0.56-0.96)	0.78 (0.59-0.98)	0.75 (0.57-0.95)	0.77 (0.59-0.99)	0.90 (0.65-1.24)	0.78 (0.59-0.99)	0.78 (0.61-0.97)	—
C vs A+CL	1.49 (0.63-2.93)	1.48 (0.66-3.13)	1.54 (0.64-3.08)	1.57 (0.67-3.42)	1.53 (0.62-3.30)	-	1.47 (0.62-3.04)	1.49 (0.64-3.03)	—
A+C vs TF	1.17 (0.90-1.52)	1.28 (0.95-1.68)	1.27 (0.96-1.66)	1.27 (0.96-1.66)	1.27 (0.95-1.67)	1.13 (0.81-1.54)	1.16 (0.88-1.50)	1.16 (0.90-1.47)	—
A+C vs CL	0.81 (0.63-1.05)	0.79 (0.61-1.03)	0.81 (0.63-1.05)	0.79 (0.62-1.03)	0.81 (0.63-1.05)	0.81 (0.61-1.11)	0.81 (0.63-1.05)	0.81 (0.65-1.04)	—
A+C vs A+CL	1.58 (0.67-3.11)	1.60 (0.72-3.33)	1.63 (0.69-3.24)	1.69 (0.73-3.59)	1.63 (0.67-3.43)	—	1.55 (0.67-3.20)	1.58 (0.70-3.19)	1.49 (0.65-3.38)
TF vs CL	0.69 (0.51-0.98)	0.62 (0.43-0.89)	0.65 (0.47-0.91)	0.63 (0.45-0.89)	0.64 (0.46-0.92)	0.72 (0.50-1.08)	0.70 (0.50-1.00)	0.70 (0.53-0.96)	—
TF vs A+CL	1.16 (0.56-2.78)	1.08 (0.54-2.70)	1.09 (0.52-2.70)	1.12 (0.55-3.03)	1.08 (0.51-2.94)	—	1.14 (0.57-2.94)	1.16 (0.57-2.86)	—
CL vs A+CL	1.96 (0.79-3.99)	2.02 (0.87-4.43)	2.01 (0.81-4.18)	2.13 (0.87-4.68)	2.02 (0.79-4.43)	—	1.92 (0.79-4.11)	1.93 (0.78-4.02)	—

Random effects model was used; A, aspirin; D, dipyridamole; P, placebo; TF, triflusal; TC, ticlopidine; CL, cilostazol; C, clopidogrel; A1, aspirin 30-50 mg daily; A2, aspirin 75-162 mg daily; A3, aspirin 283-330 mg daily; A4, aspirin 500-1500 mg daily; AD1, aspirin 50 mg plus dipyridamole 400 mg daily; AD2, aspirin 990-1300 mg plus dipyridamole 150-300 mg daily; for all of the table cells, odds ratios <1 favor the right regimens; for network meta-analysis, "—" indicates that the corresponding regimens were excluded by sensitivity analysis; for direct comparison, "—" indicates that no direct comparison is available; *statistical heterogeneity was found (P-for-heterogeneity < 0.1 or I^2 > 50%).